Familial Mediterranean Fever Clinical Trial
— FMFOfficial title:
Evaluation of Bone Metabolism in Children and Adolescents With Familial Mediterranean Fever and Correlation With Genotype
NCT number | NCT06034795 |
Other study ID # | q3e689cu |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 8, 2022 |
Est. completion date | January 2025 |
Familial Mediterranean Fever is a chronic auto-inflammatory disease. In the context of chronic inflammation, it seems that, among others, it also affects bone density in children. Bone loss may be due to subclinical inflammation that persists even during periods of remission. In addition, inflammatory cytokines also play an important role (mainly during episodes) resulting in an increase in bone degradation and ultimately a reduction in bone mass. Cytokines mainly associated with bone degradation and osteoclast activity are: IL-1R, IL-2, IL-6, IL-8, TNFa. The purpose of this study is to determine the effect of FMF on bone density and to compare the results with a healthy population. In addition, the difference between the children with FMF will be studied according to the mutation they carry.
Status | Recruiting |
Enrollment | 62 |
Est. completion date | January 2025 |
Est. primary completion date | January 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Years to 20 Years |
Eligibility | Inclusion Criteria: - For patients: - Age > 6 years - BMI 3rd - 90th percentile - Meet the Tel Hashomer criteria (Avi Linhnen 1997) - Confirmed diagnosis by finding mutation(s) in the MEFV gene - Taking medication (colchicine) for at least 3 months - Normal physical activity during the last month, according to the questionnaire that will be distributed - Free individual history for bone diseases - Normal thyroid function - For the control group: - Age > 6 years - BMI 3rd - 90th percentile - Free individual history for bone diseases - Normal physical activity according to the questionnaire - Normal thyroid function Exclusion Criteria: - For patients: - Age < 6 years - BMI < 3rd or > 90th percentile - Period of attack period of the disease - Those who have not started treatment with colchicine - Those who do not adapt well to taking colchicine - Decreased physical activity during the last month according to the questionnaire - Finding from the history of bone diseases that could affect the results - Taking vitamins that could affect the results - Existence of a factor that does not allow the performance of Dexa (when for example the safe and appropriate placement of the child cannot be ensured) - History of previous surgery which forced the patient to be bedridden for a significant period of time. Possible unreliable result of bone mineral density measurement due to reduced physical activity. - For the control group: - Age < 6 years - BMI < 3rd or > 90th percentile - Taking vitamins that could affect the results - Decreased physical activity during the last month according to the questionnaire - History of previous surgery in the last year |
Country | Name | City | State |
---|---|---|---|
Greece | Papageorgiou General Hospital | Thessaloníki | Municipality Of Pavlou Mela |
Lead Sponsor | Collaborator |
---|---|
Aristotle University Of Thessaloniki | Papageorgiou General Hospital |
Greece,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effect of chronic inflammation of FMF on bone metabolism | This study will include 62 children, 31 healthy and 31 with FMF.
All children will undergo: 1. Blood examination that will include check of calcium metabolism, Vitamin D levels, kidney function, hormonal control, thyroid function control. Biomarkers of the RANK/RANKL/OPG, which have a major role in osteoblast/osteoclast activity, will be tested. The subjects will be devided according to gender and age: 2 age groups: a) 6-12 years, b) 12 - 20 years. All the parameters will be compared to check if there is statistically significant difference between healthy children and children with FMF. |
The evaluation of bone mineral density will take place for children with FMF at attack free periods and for control group at periods that they are completely healthy. The maximun duration of the above control will be 24 hours. | |
Primary | Effect of chronic inflammation of FMF on bone density | All children will undergo:
2. Bone density measurment by Dual Energy X-ray Absorptiometry (the most reliable method for imaging bone density and with the minimum radiation). We will check z-score of Lumbar spine and z-score of Total Body Less Head. |
The evaluation of bone mineral density will take place for children with FMF at attack free periods and for control group at periods that they are completely healthy. The maximun duration of the above control will be 24 hours. | |
Primary | Effect of obesity on chronic inflammation of FMF | We will measure Body Mass Index (BMI) in all subjects. We will measure weight in kilograms (kg) and height in meters (m) to arrive at one reported value of BMI in kg/m^2. | The evaluation of bone mineral density will take place for children with FMF at attack free periods and for control group at periods that they are completely healthy. The maximun duration of the above control will be 24 hours. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00658060 -
Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients
|
N/A | |
Withdrawn |
NCT05448391 -
A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)
|
Phase 2 | |
Recruiting |
NCT05190991 -
Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
|
Phase 2 | |
Completed |
NCT00094900 -
Interleukin-1 Trap to Treat Autoinflammatory Diseases
|
Phase 2 | |
Not yet recruiting |
NCT06033339 -
Assessment of microRNAs Role in Familial Mediterranean Fever FMF Pathophysiology
|
N/A | |
Completed |
NCT01705756 -
Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever
|
Phase 3 | |
Recruiting |
NCT06338891 -
Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks
|
||
Recruiting |
NCT05596643 -
Investigation of Autonomic Dysfunction in Patients With Familial Mediterranean Fever
|
||
Enrolling by invitation |
NCT02175589 -
Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation
|
Phase 2 | |
Completed |
NCT05177120 -
Central Sensitization in Familial Mediterranean Fever (FMF)
|
||
Active, not recruiting |
NCT06257342 -
Physical Abilities of Teenagers With Familial Mediterranean Fever
|
||
Recruiting |
NCT04478409 -
Characterization of a Functional Test for Mediterranean Family Fever Screening - 2
|
||
Completed |
NCT04729218 -
The Movement Imagery Ability in Patients With Familial Mediterranean Fever
|
||
Terminated |
NCT01059279 -
Heat Intolerance in the Group of FMF Patients
|
||
Enrolling by invitation |
NCT04724993 -
Effects of Online Aerobic Exercise Training and Physical Activity Counseling in Juvenile Familial Mediterranean Fever
|
N/A | |
Completed |
NCT03747315 -
A Diagnostic Test for Familial Mediterranean Fever
|
||
Completed |
NCT01075906 -
Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients
|
Phase 1 | |
Withdrawn |
NCT00323440 -
Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission
|
N/A | |
Completed |
NCT00582907 -
Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
|
Phase 2 | |
Not yet recruiting |
NCT05488561 -
Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings
|
N/A |